Apple has successfully obtained a temporary reprieve from a U.S. government ban on the sale of certain Apple Watch models. This ruling comes after the U.S. International Trade Commission (ITC) determined in October that Apple had infringed upon two patents held by medical technology company Masimo and its sister company Ceracor Laboratories. The patents in question relate to the sensors used to measure blood oxygen levels in devices such as the Apple Watch Series 9 and Apple Watch Ultra 2.
As of now, “the government is directed not to enforce the Remedial Orders until further notice while the court considers the motion for a stay pending appeal,” stated the court in a concise two-page order.
Apple Halts Sales of Series 9 and Ultra 2 Watches Following U.S. ITC Decision
Apple has recently ceased the sale of Series 9 and Ultra 2 watches in response to a final ruling by Tai. As of Wednesday, both models are labeled as “currently unavailable” on Apple.com.
In a statement issued on Tuesday, Apple expressed strong disagreement with the decision made by the U.S. ITC and the subsequent exclusion order. The company reassured customers that it is committed to taking necessary measures to promptly make Apple Watch Series 9 and Apple Watch Ultra 2 available in the U.S. once again.
However, it is important to note that the ITC order does not impact watches that are already being used. Apple Watch SE models continue to be available for purchase both online and in stores.
Apple is actively exploring various legal and technical options in order to resume the sales of Apple Watch Series 9 and Apple Watch Ultra 2. The company has additionally submitted a proposed redesign for these models to seek approval from U.S. Customs.
At this time, neither Apple nor Masimo have responded to the Federal Circuit court’s ruling.
In the midst of these developments, Apple’s stock price dipped by 0.3% to $192.45 during Wednesday’s trading session, while Masimo experienced a 2.9% decline to $117.10.
